264 related articles for article (PubMed ID: 36948848)
1. [Demographic characteristics and associated influencing factors in treated patients with chronic hepatitis B with hypoviremia : a single-center retrospective cross-sectional study].
Li T; Kong Y; Liu YY; Liu TF; Ma AD; Li LQ; Pei ZY; Zhang LY
Zhonghua Gan Zang Bing Za Zhi; 2023 Jan; 31(1):42-48. PubMed ID: 36948848
[No Abstract] [Full Text] [Related]
2. [Analysis of efficacy and factors influencing sequential combination therapy with tenofovir alafenamide fumarate after treatment with entecavir in chronic hepatitis B patients with low-level viremia].
Liu LP; Wu XP; Cai TP; Wang L; Sun J; Liang JY; Ma SP; Gan X; Ruan NH; Ge SF
Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):118-125. PubMed ID: 37137825
[No Abstract] [Full Text] [Related]
3. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
[TBL] [Abstract][Full Text] [Related]
4. Risk factors of low-level viremia in chronic hepatitis B patients receiving Entecavir monotherapy: a retrospective cohort study.
Chen H; Fu JJ; Li L; Wang X; Pan XC
J Gastroenterol Hepatol; 2024 Jan; 39(1):180-184. PubMed ID: 37718592
[TBL] [Abstract][Full Text] [Related]
5. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir.
Lee JM; Ahn SH; Kim HS; Park H; Chang HY; Kim DY; Hwang SG; Rim KS; Chon CY; Han KH; Park JY
Hepatology; 2011 May; 53(5):1486-93. PubMed ID: 21520167
[TBL] [Abstract][Full Text] [Related]
6. [Liver histological status and clinic outcome in HBeAg-negative chronic hepatitis B with low viral load].
Deng DL; Jiang JN; Su MH; Wang RM; Zang WW; Ling XZ; Wei HL; Liang XS; Zhou HK; He WM; Guo RS
Zhonghua Gan Zang Bing Za Zhi; 2020 Dec; 28(12):1013-1017. PubMed ID: 34865348
[No Abstract] [Full Text] [Related]
7. [Analysis of clinical characteristics of persistent HBeAg positivity in patients with chronic hepatitis B treated with nucleos(t)ide analogues].
Peng LP; Gan WQ; Zheng YB; Chen YM; Liu J; Wu ZB; Gao ZL
Zhonghua Gan Zang Bing Za Zhi; 2024 Mar; 32(3):193-200. PubMed ID: 38584099
[No Abstract] [Full Text] [Related]
8. Liver histopathological lesions is severe in patients with normal alanine transaminase and low to moderate hepatitis B virus DNA replication.
Jiang SW; Lian X; Hu AR; Lu JL; He ZY; Shi XJ; Zhu DD; Wang ZY; Huang GC
World J Gastroenterol; 2023 Apr; 29(16):2479-2494. PubMed ID: 37179582
[TBL] [Abstract][Full Text] [Related]
9. [A study of the effectiveness of nucleos(t)ide analogues in the treatment of HBeAg- positive chronic hepatitis B with normal alanine aminotransferase and high level of HBV DNA].
Wang FD; Zhou J; Zhang DM; Wang ML; Tao YC; Wu DB; Tang H; Chen EQ
Zhonghua Gan Zang Bing Za Zhi; 2022 Apr; 30(4):389-394. PubMed ID: 35545563
[No Abstract] [Full Text] [Related]
10. [Clinical effect of entecavir versus tenofovir in treatment of HBeAg-positive chronic hepatitis B patients with a high viral load: a comparative analysis].
Shi H; Li XY; Zhu JY; Lin CS; Zhang Y
Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):721-725. PubMed ID: 29108198
[No Abstract] [Full Text] [Related]
11. Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <2,000 IU/mL.
Lee HW; Park SY; Lee YR; Lee H; Lee JS; Kim SU; Park JY; Kim DY; Ahn SH; Kim BK
Am J Gastroenterol; 2022 Feb; 117(2):288-294. PubMed ID: 34506308
[TBL] [Abstract][Full Text] [Related]
12. Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy.
Liu R; Guo J; Lu Y; Zhang L; Shen G; Wu S; Chang M; Hu L; Hao H; Li M; Xie Y
Clin Exp Med; 2019 Aug; 19(3):309-320. PubMed ID: 31111345
[TBL] [Abstract][Full Text] [Related]
13. [Analysis and significance of HBV DNA below the lower detection limit of HBV RNA levels after long-term NAs antiviral therapy in patients with hepatitis B virus cirrhosis].
Wang CY; Cao Y; Feng YM; Li J; Jiang B; Zhang Y; Wen J; Zhu YJ; Li J
Zhonghua Gan Zang Bing Za Zhi; 2022 Jul; 30(7):758-762. PubMed ID: 36038347
[No Abstract] [Full Text] [Related]
14. Quantitative hepatitis B surface antigen titres in Chinese chronic hepatitis B patients over 4 years of entecavir treatment.
Chen EQ; Wang TT; Bai L; Tao CM; Liang T; Liu C; Liao J; Tang H
Antivir Ther; 2013; 18(8):955-65. PubMed ID: 23639885
[TBL] [Abstract][Full Text] [Related]
15. [Predictive Value of Baseline Serum Marker Levels for the Effect of Interferon Therapy in Patients With Chronic Hepatitis B].
Yan Y; Davgadorj C; Lyu C; Lu Z; Yu P
Sichuan Da Xue Xue Bao Yi Xue Ban; 2024 Mar; 55(2):383-390. PubMed ID: 38645851
[TBL] [Abstract][Full Text] [Related]
16. Serum hepatitis B virus ribonucleic acid and its influencing factors in chronic hepatitis B.
Zhou Y; Peng Y; Yuan H; Long Z; Wu S; Yang J
Adv Clin Exp Med; 2021 Apr; 30(4):361-367. PubMed ID: 33928768
[TBL] [Abstract][Full Text] [Related]
17. Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues.
Wang Y; Liao H; Deng Z; Liu Y; Bian D; Ren Y; Yu G; Jiang Y; Bai L; Liu S; Liu M; Zhou L; Chen Y; Duan Z; Lu F; Zheng S
J Viral Hepat; 2022 Jun; 29(6):420-431. PubMed ID: 35274400
[TBL] [Abstract][Full Text] [Related]
18. Serum HBV DNA plus RNA reflecting cccDNA level before and during NAs treatment in HBeAg positive CHB patients.
Wang Y; Liu Y; Liao H; Deng Z; Bian D; Ren Y; Yu G; Jiang Y; Bai L; Liu S; Liu M; Zhou L; Chen Y; Chen X; Duan Z; Lu F; Zheng S
Int J Med Sci; 2022; 19(5):858-866. PubMed ID: 35693741
[No Abstract] [Full Text] [Related]
19. Effect of nucleos(t)ide analogue on serum HBsAg level in chronic hepatitis B patients: A 3-years study.
Zheng Z; Liao W; Liu L; Cai S; Zhu H; Yin S
Biomed Pharmacother; 2020 Feb; 122():109698. PubMed ID: 31918272
[TBL] [Abstract][Full Text] [Related]
20. [Clinical characteristics of hepatic flare and efficacy of antiviral therapy in pregnant women with chronic hepatitis B virus infection].
Ding Y; Sheng QJ; Zhang C; Wu YY; Yuan SY; Xia TT; An ZY; Dou XG
Zhonghua Gan Zang Bing Za Zhi; 2019 Feb; 27(2):106-111. PubMed ID: 30818914
[No Abstract] [Full Text] [Related]
[Next] [New Search]